Bioscience - Lost in Translation?
A New Era
Richard Barker, Professor of Medical Innovation Science at the University of Oxford, Founder and Director of the Centre for the Advancement of Sustainable Medical Innovation (CASMI) and Chair of the UK government Precision Medicine Catapult, is launching his new book -
Join us to discuss the challenges, and the opportunities, in the translation of biomedical innovation.
18:15-18:30 - Introduction
18:30-19:30 - Panel Discussion: 'Lost in Translation'
19:30-20:00 - Close by Richard Barker
20:00-20:30 - Drinks and networking
Bioscience - Lost in Translation
The 21st century, we are told, is the century of bioscience, promising an opportunity to revolutionise human health. More than 2 million academic biomedical science papers are published each year; over 14,000 patents are filed; literally thousands of possible new drugs are studied - the statistics are impressive and rising.
Despite governments and private industry investing more heavily in life sciences than any other field, only 30-40 new drugs a year are approved after more than 10 years of effort and millions of dollars spent in clinical trials. Only a small handful of cell and gene therapies reach patients, despite more than 2 decades of investment in these powerful new regenerative medicine modalities. In addition, many of the new treatments that we do produce reach only a small fraction of patients who could benefit. Digital health fails to deliver the revolution in how we manage and monitor our health that we are promised. What’s going on?
In bioscience, somehow, somewhere, science is getting ‘lost in translation’. Some blame industry, some regulators, some over-conservative doctors, some stingy health systems, for the growing innovation gap between what now seems possible and what actually results in patient benefit and new models of care.
An overhaul of the innovation system for life sciences seems called for. And indeed worried governments, challenged by ever more activist patients, are launching exciting-sounding initiatives like 21st Century Cures in the US or the Accelerated Access Review in the UK. But can they make the crucial difference, close the innovation gap and bring life-changing products to patients and transformations to the health system? Government motivation is two-fold - to improve the health of their populations but also to generate economic growth and so secure better returns for their rising spend in bioscience.
There may be a golden thread that runs through most of the solutions we need if we are to address this failure in translation – Precision Medicine. We are learning how the molecular basis of disease can help us find more targeted treatments and then match them to those patients most likely to benefit, making new therapies more inexpensively trialled, more successfully licensed, more affordably reimbursed and more readily adopted. Precision Medicine holds the promise of reshaping our innovation ecosystem so we can target our limited resources to maximise healthy human lifespan - which should surely be the goal of every health system on the planet.
The book is available from Amazon here.
About the author:
Richard Barker OBE is Professor of Medical Innovation Science at the University of Oxford, Founder and Director of the Centre for the Advancment of Sustainable Medical Innovation (CASMI) and Chair of the UK government Precision Medicine Catapult. Richard’s 25-year business career has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. Most recently he was Director General of the Association of the British Pharmaceutical Industry, member of the Executive Committee of EFPIA (the European industry association) and Council member of IFPMA (the international equivalent). He is a strategic advisor, speaker and author on healthcare and life sciences.
- George Freeman MP, ex UK Minister for Life Sciences
- Professor Jeremy Farrar, Executive Director, The Wellcome Trust UK
- Mike Rawlins, Chairman, National Institute for Health and Clinical Excellence (NICE)
- Janet Woodcock, Director, the Centre for Drug Evaluation and Research (CDER), FDA
- Richard Bergstrom, Director General, the Association of the Pharmaceutical Industry (LIF), Sweden
- Dr Barbara Lopez Kunz, Global Chief Executive, Drug Information Association, Switzerland
- Professor Sir John Tooke, co-Chair of the Centre for the Advancement of Sustainable Medical Innovation, UK, former Vice-Provost of University College London, and former President of the UK Academy of Medical Sciences
- Dr Michael Friedman, Emeritus Chief Executive, City of Hope Cancer Center, Duarte, CA, USA
- Mike Casey, board member and former Chief Executive of multiple US biotech companies and former senior executive at Johnson & Johnson
- Stephen P. Spielberg, MD, PhD, former Dean, Dartmouth Medical School, Hannover, NH, USA, former Deputy Commissioner, US FDA, USA, and Editor-in-Chief, Therapeutic Innovation and Regulatory Science